JOHN M. LEONARD - 01 Mar 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: President and CEO, Director
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 01 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2026, 16:19:05 UTC
Previous filing: 07 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LEONARD JOHN M	President and CEO, Director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE	James Basta, attorney-in-fact	03 Mar 2026	0001563584

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+156,400	+15%	$0.000000	1,169,739	01 Mar 2026	Direct	F1
holding	NTLA	Common Stock						58,415	01 Mar 2026	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+225,400		$0.000000	225,400	01 Mar 2026	Common Stock	225,400	$13.78	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	Shares held by the John M. Leonard 2015 Irrevocable Trust.
F3	This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.